NCT06604377Completed
Model of Predicting Biochemical Recurrence After Radical Prostate Cancer Based on Pre-treatment PSMA PET / MR Image Features
Source: ClinicalTrials.gov · Last updated 19 Sept 2024
Brief summary (registry, in English)
The purpose of this study is to investigate the predictive value of preoperative 18F-PSMA-1007 PET/MR in the predictive effect of biological recurrence (BCR) after radical prostatectomy (RP) for localized prostate cancer (PCa).
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 203 (actual)
- First submitted
- 11 Sept 2024
- Start date
- 1 Nov 2023
- Primary completion date
- 30 Jun 2024
- Lead sponsor
- Ruijin Hospital
- Diseases
- Prostate cancer
- NCT number
- NCT06604377
What you commit to
- Study type: Observational
- Participants enrolled: 203
- From 1 Nov 2023 to the primary completion date, 30 Jun 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- 1.Surgery or endocrine therapy is performed prior to the examination
Other
- \-
Who the study is looking for
- Age ≥ 18 years
- Histologically confirmed prostate cancer without other types of malignancy -
Age in the registry: 18 years to - · Sex: Male · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Ruijin Hospital affiliated to Shanghai Jiao Tong University of Medicine Coordinator of this site? Confirm its status | Shanghai | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.